Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.

Journal of paediatrics and child health - 1 Dec 2011

Moore Andrew S, Norris Ross, Price Gareth, Nguyen Thu, Ni Ming, George Rani, van Breda Karin, Duley John, Charles Bruce, Pinkerton Ross

Abstract excerpt

BACKGROUND: Vincristine is a key component of many childhood cancer treatment regimens. Pharmacodynamic parameters such as clinical efficacy and toxicity may be influenced by polymorphisms of CYP3A. AIM: The aim of this study was to document CYP3A5 genotype, vincristine pharmacokinetics (PK) and neurotoxicity profile for 50 children with cancer and determine whether, in a population of Australian children, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Chromatography, High Pressure Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Comet Assay

Share to Cytochrome P-450 CYP3A

Share to Neoplasms

Share to Neurotoxicity Syndromes

Share to Pharmacogenetics

Share to Vincristine

Source

Identifiers

PMID: 21658147
DOI: 10.1111/j.1440-1754.2011.02103.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.PMID 21658147Read ↗

Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases.Semantic proximity Read ↗

CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.Semantic proximity Read ↗

Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.Semantic proximity Read ↗

Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.Semantic proximity Read ↗

Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.Semantic proximity Read ↗

The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.Semantic proximity Read ↗

Extrapolating Vincristine-Induced Peripheral Neuropathy From Caucasian to Kenyan Populations: Impact of Type I and Type II Selection Bias.Semantic proximity Read ↗

Genetic Polymorphisms Associated with Vincristine Pharmacokinetics and Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology PatientsSemantic proximity Read ↗

Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis.Semantic proximity Read ↗

Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.Semantic proximity Read ↗

Genomic variations associated with risk and protection against vincristine-induced peripheral neuropathy in pediatric cancer patientsSemantic proximity Read ↗

Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.